Emerging Roles for LGR4 in Organ Development, Energy Metabolism and Carcinogenesis

Linlin Yang1,2,3, Jing Wang1,2,3, Xiaodi Gong1,2,3, Qiong Fan1,2,3, Xiaoming Yang1,2,3, Yunxia Cui1,2,3, Xiaoyan Gao1,2,3, Lijuan Li1,2,3, Xiao Sun1,2,3, Yuhong Li1,2,3* and Yudong Wang1,2,3*

1Department of Gynecological Oncology, The International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China, 2Shanghai Municipal Key Clinical Specialty, Shanghai, China, 3Shanghai Key Laboratory of Embryo Original Disease, Shanghai, China

The leucine-rich repeats containing G protein-coupled receptor 4 (LGR4) belonging to G protein-coupled receptors (GPCRs) family, had various regulatory roles at multiple cellular types and numerous targeting sites, and aberrant LGR4 signaling played crucial roles in diseases and carcinogenesis. On the basis of these facts, LGR4 may become an appealing therapeutic target for the treatment of diseases and tumors. However, a comprehensive investigation of its functions and applications was still lacking. Hence, this paper provided an overview of the molecular characteristics and signaling mechanisms of LGR4, its involvement in multiple organ development and participation in the modulation of immunology related diseases, metabolic diseases, and oxidative stress damage along with cancer progression. Given that GPCRs accounted for almost a third of current clinical drug targets, the in-depth understanding of the sophisticated connections of LGR4 and its ligands would not only enrich their regulatory networks, but also shed new light on designing novel molecular targeted drugs and small molecule blockers for revolutionizing the treatment of various diseases and tumors.

Keywords: LGR4, development, immunity, metabolism, malignancy, targeted therapy

INTRODUCTION

The leucine-rich repeat-containing G protein-coupled receptors (LGRs) are highly conserved proteins of the G protein-coupled receptors (GPCRs) family, identified as multiple repeats of leucine-rich repeats (LRRs) in the extracellular domain (Luo and Hsueh, 2006). The leucines in LRRs act as the dominant hydrophobic residue and play a critical role in the interactions between proteins (Kobe and Deisenhofer, 1993; 1995), which also allow forming a unique tertiary structure (Kajava, 1998). LRRs are connected to a seven-transmembrane (TM) domain that are related to G protein activation via a cysteine-rich region (Xu et al., 2013) and exerts its biological effects by binding to the ligand (Wang D. et al., 2013). LGRs could be subdivided into three groups (groups A–C) (Barker et al., 2013). Group A is consisted of luteinizing hormone receptor (LHR), follicle-stimulating hormone receptor (FSHR) and thyroid stimulating hormone receptor (TSHR) (Van Loy et al., 2008). Group B contains LGR4, LGR5, and LGR6, which exhibit a high degree of homology and function as receptors for the Wnt-activating R-spondins (Dubey et al., 2020). Group C is consisted of LGR7 and LGR8, which recognize relaxin (Yoshino et al., 2020) and insulin-like peptide 3 (INSL3) (Yeom et al., 2021), respectively.
The leucine-rich repeat-containing GPCR 4 (also called as LGR4) molecule is 107 kb and located on chromosome 11 at position 11p14-p13. It is composed of 17 LRRs and each contains 24 amino acids (McDonald et al., 1998). LGR4 signaling plays a functional role in self-renewal of stem cells by binding to R-spondin, thus potentiating Wnt signaling. R-spondin interacts with LGR4 inhibiting the expression of ZNRF3 and RNF43, the negative mediators of Wnt signaling that induce degradation of the Wnt receptor Frz and coreceptors LRP5/6 (Hao et al., 2012), thereby elevating the concentration of Wnt receptors and increasing the signaling response. R-spondin-bound LGR4 could also bind directly to LRP6 to boost the phosphorylation of LRP6 in response to Wnt-Fzd combination (Carmon et al., 2011). Clathrin (Glinka et al., 2011) and Norrin (Deng et al., 2013) were also reported to be needed for LGR4-mediated Wnt signaling. The ligand activated LGR4 triggers G-protein through GTP binding as well. Then coupled Gas is dissociated from LGR4 and activates adenylyl cyclase (AC) elevating the level of second messenger cyclic AMP (cAMP), which activates protein kinase A (PKA) and in turn, phosphorylates cre-binding protein (CREB), thus enhancing the expression of its target genes, such as mineralocorticoid receptor (Wang et al., 2012), estrogen receptor α (Li et al., 2010). However, the ligands initiating cAMP/PKA pathway by LGR4 still remains unidentified.

Accumulating evidence supported by recent studies has shown that LGR4 is indispensable in embryonic growth, multiple organ development (Knight and Hankenson, 2014), energy metabolism (Li et al., 2014), ischemia/reperfusion injury (Li Z. et al., 2019) and the maintenance of stem cell self-renewal in intestine (Mustata et al., 2011), prostate (Luo et al., 2013), and mammary gland (Wang Y. et al., 2013). LGR4, as a new RANKL receptor, could counteract RANKL-driven osteoclastogenesis and enhance osteoblast maturation, mineralization (Luo et al., 2016) and vascular calcification (Carrillo-López et al., 2020). It also plays an oncogenic role in various human cancers, such as multiple myeloma (van Andel et al., 2017), thyroid carcinoma (Kang et al., 2017), and ovarian cancer (Wang Z. et al., 2020), etc. This paper will systematically summarize LGR4’s role in organ development, energy metabolism and tumor formation, which may provide the fundamental basis for the targeted gene therapy in the future.

METHODS

We screened MEDLINE, PubMed, and Google Scholar for relevant literatures from 2000 to 2021 and subjected the corresponding references to this review. This compiling was limited to studies written in English by using the terms “Leucine-rich repeats containing G protein-coupled receptor 4”, “LGR4”, “GPR48”, focusing on the biological function of LGR4, and various roles of LGR4 in development, immunity, energy metabolism, oxidative stress, and carcinogenesis.

SIGNAL TRANSDUCTION OF LGR4 GENE IN CELLS

LGR4 is a transmembrane receptor of the GPCRs superfamily that is characterized by a large extracellular Leucine-rich domain that recognizes and interacts with its ligands (Van Loy et al., 2008), thus regulating numerous cellular processes (Figure 1). Many studies have explored the mechanisms of LGR4 gene. Researchers demonstrated that LGR, R-spondin, and ZNRF3 or RNF43 formed a ternary complex (Hao et al., 2012; Koo et al., 2012), alleviating ZNRF3/RNF43 clearance of Frizzled-LRP Wnt coreceptor, thus activating Wnt signaling (Hao et al., 2012). Rspo-LGRs signaling is essential for embryogenesis and cell protection (Knight and Hankenson, 2014). Another study found that RSPO-LGR4-IQGAP1 promoted MEK1/2-modulated phosphorylation of LRP5/6 in β-catenin-dependent manner or regulated actin dynamics in a Wnt-independent manner, thus potentiating Wnt signaling (Carmon et al., 2014). Wang, D. et al. showed that the furin-like cysteine-rich domains of RSPO1 could interact with LGR4, thus inducing its biological activities (Wang D. et al., 2013). In addition, Park, S. et al. explored that full-length LGR4 interacted with E3 ligases RNF43 and ZNRF3 forming a complex to reduce ubiquitylation degradation of Wnt receptors and activate Wnt/β-catenin signaling (Park et al., 2020). They also explored that RSPO2 activated Wnt/β-catenin signaling with no binding to LGR4 or LGR5 (Park et al., 2018), which differentiated from other RSPO molecules (Figure 2). Moreover, Geng, A. et al. demonstrated that Rspo1 interacted with LGR4 and then activated cAMP-PKA signaling to elevate Esr1 expression and increase mammary side branches in a Wnt-independent manner (Geng et al., 2020), which provided a novel mechanism for estrogen-related diseases.

LGR4 IN ORGAN DEVELOPMENT

The Role of LGR4 Gene in the Development of Maxillofacial Organs

The gene of LGR4 was widely expressed in adrenal gland, kidney, heart, stomach, intestine, bone/cartilage and other tissues, and was first found to be associated with developmental processes (Yi et al., 2013), which was validated by immunohistochemical staining in wild-type mice. LGR4 deletion led to the severe pre- and postnatal lethality of mice explaining the significant importance of the LGR4 signaling for cell survival and growth (Mazerbourg et al., 2004). Meanwhile, LGR4 deficiency attenuated the expression of ATF4 via cAMP-PKA-CREB pathway to modulate definitive erythropoiesis (Song et al., 2008). Furthermore, LGR4 knockdown blocked GnRH neuron development by impairing Wnt/β-catenin signaling, leading to delayed puberty (DP) (Mancini et al., 2020). In addition, LGR4 regulated long term depression (LTD) at parallel fiber-PC (PF-PC) by modulating Creb signaling, suggesting its role in cerebellar ataxia (Guan et al., 2014). As a marker for hair follicle stem cell (Kim et al., 2019), LGR4 promoted the hair cycle progression by activating Akt/mTOR signaling, Wnt/β-catenin signaling and decreasing BMP signaling, thus regulating the development of
hair follicle (HF). The skin epithelia-specific deletion of LGR4 lead to reduced numbers of LGR5+, and actively proliferating HF stem cells without affecting the number of quiescent HF stem cells, resulting in compromised HF regeneration after transplantation (Ren et al., 2020). It also played a critical role in controlling hair cell differentiation in cochlea (Żak et al., 2016).

In eye development, Jin, C. et al. showed that LGR4 was highly expressed in cells of eyelids. LGR4 deficiency inhibited the phosphorylation of EGFR, thus blocking epithelial cell proliferation and migration in eyelid development (Jin et al., 2008). Additionally, LGR4 regulated keratinocyte proliferation through EGFR signaling pathway and the inhibitor of EGFR tyrosine kinase or its ligand HB-EGF could suppress cellular processes (Wang et al., 2010). The keratinocyte motility was reduced in LGR4 deleting mice leading to eye-open at birth (EOB) phenotype (Kato et al., 2007). Weng, J. et al. showed that deletion of LGR4 downregulated Pitx2 via cAMP-CREB signaling, thus inducing ocular anterior segment dysgenesis (ASD) (Weng et al., 2008). Further, the antioxidant enzymes CAT and SOD1 were downregulated in the lens epithelial cells of LGR4 deficiency mice, resulting in cataract formation (Zhu et al., 2015). MicroRNA let-7b promoted the apoptosis of lens epithelial cell by targeting LGR4, thus inducing ocular anterior segment dysgenesis (ASD) (Weng et al., 2008). Further, the antioxidant enzymes CAT and SOD1 were downregulated in the lens epithelial cells of LGR4 deficiency mice, resulting in cataract formation (Zhu et al., 2015). MicroRNA let-7b promoted the apoptosis of lens epithelial cell by targeting LGR4, thus inducing ocular anterior segment dysgenesis (ASD) (Weng et al., 2008).

LGR4 in Bone Differentiation and Mineralization

LGR4 was believed to be a novel receptor for RANKL, it could induce the cAMP-PKA-CREB signaling to control the expression of Atf4 and its target genes Ocn, Bsp and collagen in osteoblasts. LGR4 deficiency in murine led to a delay in osteoblast differentiation, while increasing the activity of osteoclasts, thus regulating bone remodeling (Luo et al., 2009). LGR4 could also compete with the canonical receptor RANK to bind RANKL, suppress RANKL-RANK-TRAF6 signaling cascade and activate the Gαq and GSK3-β signaling, thus inhibiting the activity of NFATC1 and blocking RANKL-induced osteoclast differentiation (Luo et al., 2016). Jang, Y. et al. identified that the mutated RANKL protein acted as a competitive inhibitor of RANKL, bound only to the receptor LGR4, induced GSK-3β phosphorylation and inhibited NFATc1 nuclear translocation, and thereby preventing osteoclast differentiation (Jang et al., 2021). Additionally, miR-34c promoted osteoclast differentiation through targeting LGR4, activating NF-κB and GSK3-β signaling (Cong et al., 2017). LGR4 was found to be preferentially expressed in osteoblasts and played a vital role in canonical Wnt signaling, thus regulating osteoblastogenesis and bone homeostasis (Zhang et al., 2021). MiR-193a-3p inhibited
osteoblast differentiation through regulating LGR4/ATF4 signaling (Wang et al., 2018). Zhang, M. et al. reported that RSPO3-LGR4 system inhibited osteogenesis of human adipose-derived stem cells by negatively regulating ERK/FGF signalling (Zhang M. et al., 2017). The compressive force (CF) in alveolar bone led to the elevation of RANK and decrease of LGR4, thus inducing bone differentiation (Matsuike et al., 2018). LGR4 played an essential role in the sequential development of molars by Wnt/β-catenin/LEF1 signaling (Yamakami et al., 2016). The silencing of LGR4 suppressed proliferation and osteogenic differentiation of stem cells from apical papillae (SCAPs) through inhibiting the Wnt/β-catenin pathway (Zhou et al., 2017). Arima, M. et al. reported that RSPO2-LGR4 accelerated osteoblastic differentiation by Wnt/β-catenin signaling in immature human periodontal ligament cells (Arima et al., 2019).

Further study indicated that there was a close correlation between LGR4 genotypes and bone mineral density (BMD), including the association between rs11029986 of LGR4 and total fat mass (TFM) (Yu et al., 2020). Additionally, researchers identified that a rare nonsense mutation within LGR4 gene (c.376C>T) was strongly associated with lower BMD and osteoporotic fractures by whole-genome sequencing of Icelandic individuals (Styrkarsdottir et al., 2013). Meanwhile, by the technology of next generation sequencing (NGS), Li, C. et al. showed that LGR4 was significantly differentially expressed between postmenopausal cases with impaired BMD and control group with normal values (Li C. et al., 2020). Moreover, a study also reported that LGR4-deficiency inhibited the differentiation of bone marrow mesenchymal stem cells (BMSCs), reduced bone mass, thus suppressing fracture healing (Sun et al., 2019). MiR-137 was correlated...
with an increased risk of fracture in patients with osteoporosis by targeting LGR4/ALP expression (Liu and Xu, 2018). In addition, a latest finding showed that the novel RANKL variant induced the expression of LGR4 by the GSK3-β signaling, thus suppressing the activity of NFATc1 and inhibiting osteoporosis (Ko et al., 2021). Shi, G. X. et al. identified that Rspo1/LGR4 could enhance osteogenesis by Wnt/β-catenin signaling. Loss-of-function experiments indicated that LGR4 deficiency resulted in decreased osteogenic effects together with aerobic glycolysis (Yang et al., 2021). The above studies revealed the important mechanisms of LGR4 in bone differentiation and development, indicating its great potential in the treatment of osteolysis diseases.

LGR4 Gene in the Development of Heart, Liver, Kidney, Gonads, and Other Important Organs

Recent study indicated that Rspo3-LGR4 axis played a crucial role in heart development (Da Silva et al., 2018). LGR4 was found to be a molecular biomarker for cardiac progenitors (den Hartogh et al., 2016). In addition, study found that RSPO-LGR4/5-ZNRF3/RNF43 system regulated metabolic liver zonation by Wnt/β-catenin signalling (Planas-Paz et al., 2016). In contrast, Planas-Paz, L. et al. explored that LGR4/5-modulated WNT/β-Catenin signaling was dispensable for ductular reaction (DR) in biliary epithelial cells (BECs), while YAP and mTORC1 signaling were necessary for this process. LGR5 and AXIN2 were detected in hepatocytes to facilitate liver regeneration (Planas-Paz et al., 2019). More researches were needed on the important role of LGR4 gene in liver metabolism. Additionally, researchers proposed that the N-termini and 7TM domains of LGR5/LGR4 modulated WNT signaling in a ligand-dependent manner, while their C-termini and rhodopsin-like 7TM domains activated NF-κB signaling in a ligand-independent manner to control the survival of LGR5+ stem cells and intestinal crypts (Lai et al., 2020). Moreover, Dang, Y. et al. identified that the deficiency of LGR4 led to polycystic lesions and renal fibrosis by regulating Wnt/PCP signaling but not the TGF-β/Smad pathway (Dang et al., 2014). The serious renal hypoplasia was observed in LGR4 null mice (Kato et al., 2006). Conversely, Vidal, V. P. et al. explored that knockout of LGR4/5/6, the receptors of R-spondins, did not intervene with MET of nephron progenitor, revealing LGR-independent role in kidney development (Vidal et al., 2020). It was possible that the differences in mouse species and experimental conditions led to the differences in conclusion. A study revealed that high parathyroid hormone (PTH) elevated the expression of LGR4 and RANKL to facilitate vascular calcification (VC) by PTH1R/PKA activation (Carrillo-López et al., 2020). Luo, W. et al. identified that LGR4 promoted prostate development and stem cell differentiation by Wnt, Hedgehog and Notch1 signaling (Luo et al., 2013). The secretome from activation of stromal-androgen receptor (AR) maintained the basal state of epithelial cells by LGR4/β-Catenin/ΔNP63α signaling and did not induce the clonogenic growth of benign prostate hyperplasia (BPH) (Chauhan et al., 2020). In addition, researchers found that LGR4, not LGR5 was indispensable for the hematopoietic differentiation of human pluripotent stem cells (hPSCs) by regulating transforming growth factor beta (TGFB-beta)-SMAD2/SMAD3 signaling, thus controlling mesoderm induction and hematopoietic development (Wang Y. et al., 2020).

In mammary gland, LGR4 induced the expression of Sox2 to facilitate mammary development via Wnt/β-catenin/Lef1 signaling pathway (Wang Y. et al., 2013). LGR4 could also promote corpus luteum maturation by WNT-mediated EGFR-ERK signaling, thus maintaining female fertility (Pan et al., 2014). Hsu, P. J. et al. explored that the LGR4 splice variant which encoded only the ectodomain of LGR4 (LGR4-ED) acted as an antagonist to suppress the LGR4/RSPO2/ Norrin-mediated Wnt signaling thus controlling gonadal development (Hsu et al., 2014). Meanwhile, LGR4 could activate ESRalph by cAMP/PKA signaling to control the development of male reproductive tract (Li et al., 2010), and LGR4 inactivation led to the abnormal organization of it (Mendive et al., 2006). Hoshii, T. et al. explored that LGR4 knockout reduced the expression of estrogen receptor (ESR1), controlling elongation and differentiation of epididymal ducts (Hoshii et al., 2007). Further study explored that abnormal development of female gonads was observed in LGR4 (−/−) female mice. Rspo1/LGR4 was essential for ovarian somatic cell development via the Wnt/beta-catenin/Lef1/Axin2 signaling (Koizumi et al., 2015). In uterine receptivity, Kida, T. et al. explored that the phosphorylated PR was significantly reduced and persistent epithelial E2 receptor α was activated in LGR4 knockout mice, leading to impaired uterine receptivity (Kida et al., 2014). The reduced uterine glands and deciduization was observed in LGR4 knockout female mice by decreasing the secretion of LIF, implying the function of LGR4 in uterine gland development (Sone et al., 2013). Moreover, Gaq/11-coupled LGR4 promoted uterine receptivity by triggering PR signaling (de Oliveira et al., 2019). MiR-449a could promote caprine endometrial receptivity by targeting 3′-untranslated region of LGR4 (An et al., 2017). By using a bovine endometrial epithelial cell inflammation model and a mouse lipopolysaccharide-mediated endometritis model, the author confirmed that miR-34a/miR-193a-3p was upregulated by IL-1β and suppressed the level of the LGR4 3′UTR, which in turn amplified the inflammatory response through activating the phosphorylation of NF-κB p65 pathway, suggesting miR-34a/miR-193a-3p-LGR4 playing a pivotal role in endometritis (Ma et al., 2021; Yin et al., 2021). Furthermore, the gene of LGR4 modulated a WNT-NR5A2 signaling cascade facilitating the secretion, maturation and steroidogenesis of oviduct epithelial cells to safeguard the development and function of oviduct in mice (Tan et al., 2021). Other studies reported that akermanite
TABLE 1 | Diverse roles of LGR4 in organ development.

| Organ development | Signaling | Effect | References |
|-------------------|-----------|--------|------------|
| Cerebellum        | LGR4-Creb signaling | LGR4 (−/−) mice led to impairing long term depression | Guan et al. (2014) |
| Hair follicle     | LGR4-Akt/mTOR signaling, Wnt/β-catenin signaling and decreasing BMP signaling | LGR4 promotes the normal hair cycle | Ren et al. (2020) |
| Facial organs     | WNT1b; RSPO-2-WNT/β-catenin | Wnt1b; Rspo2 double mutant mice displayed facial defects | Jin et al. (2020) |
| Pubertal develop. | LGR4-Wnt/β-catenin signaling | Mice deficient in LGR4 had delayed onset of puberty | Mancini et al. (2020) |
| Ocular cells      | MicroRNA let-7b-LGR4; LGR4-cAMP-CREB-βcatenin | The antioxidant enzymes were decreased in LGR4 (−/−) mice | Jin et al. (2008); Weng et al. (2008); Wang et al. (2010); Zhu et al. (2015); Dong et al. (2016) |
| Liver             | RSPO-LGR4/5-ZNRF3/RNF43- Wnt/β-catenin | Recombinant RSPO1 protein increased liver size | Pianas-Paz et al. (2016) |
| Kidney            | LGR4-WNT signaling; LGR4-cAMP-CREB-JmjD2A/Fbx10; MR-34a-LGR4 | LGR4 deficiency led to poly cystic lesions and renal fibrosis | Dang et al. (2014); Yi et al. (2014); Hou et al. (2016) |
| Intestine         | LGR5-4/5-αβ and WNT signaling | LGR5/LGR4 promoted the growth of intestinal crypts | Lai et al. (2020) |
| Vascular cells    | PTH-PTHrP/PKA-LGR4 | High PTH increases LGR4 thereby favours vascular calcification | Carrillo-Lopez et al. (2020) |
| Hematopoietic cell | LGR4-CAMP-PKA-CREB-ATF4; R-spondin1/R-spondin3/LGR4/ZNRF3-TGF-beta-SMAD2/SMAD3 signaling | LGR4−/− fetuses displayed anemia, deletion of LGR4 limited hematopoietic differentiation | Song et al., 2008; Wang et al., 2020b |
| Osteoclast        | LGR4-Gaq-GSK3-β-NFATC1; RSPO-LGR4-IQGAP1-Wnt/β-catenin; MR-34c-LGR4-β3/β5-GSK3-β; MR-137-LGR4-ALP; RANKL-GSK3-β signaling-LGR4 | LGR4 deficiency exhibit osteoclast hyperactivation | Carmon et al. (2014); Luo et al. (2016); Cong et al. (2017); Liu and Xu. (2018); Park et al. (2020); Jang et al. (2021); Ko et al. (2021) |
| Osteoblast        | LGR4-CAMP-PKA-CREB-Arf4; LGR4-WNT/β-catenin; MR-193a-3p-LGR4/ATF4; RSPO-3-LGR4-ERK/FGF; RSPO1-2-LGR4-Wnt/β-catenin; LGR4-Wnt/β-catenin-pdk1/LEF1 | Deletion of LGR4 results in a delay in osteoblast differentiation | Luo et al. (2009); Yamakami et al. (2016); Shi et al. (2017); Zhang et al. (2017a); Zhou et al. (2017); Wang et al. (2018); Arima et al. (2019); Yang et al. (2021); Zhang et al. (2021) |
| Gonads            | LGR4-ED-LGR4/RSP02/Norrin-Wnt; RSPO1-LGR4-Wnt/β-catenin- Left/Alx2; LGR4-WNT/EGFR-ERK signaling | LGR4-ED acted as an antagonist controlling gonadal development | Hsu et al. (2014); Pan et al. (2014); Koizumi et al. (2015) |
| Mammary gland     | LGR4-Wnt/β-catenin/Lef1-Sox2; Rspo1-LGR4-cAMP-PKA-Esr1 | LGR4 (−/−) mice had delayed ductal development | Wang et al. (2013c); Geng et al. (2020) |
| Prostate          | LGR4-Wnt, Notch, Sonic Hedgehog signaling; LGR4/β-Catenin/ΔNP63α; LGR4-cAMP/PKA-ErAlpha | LGR4 loss blocked differentiation of prostate cells | Li et al. (2010); Luo et al. (2013); Chauhan et al. (2020) |
| Uterine           | LGR4-PR/LIF, Gaq/11-LGR4-PR; MR-449a-LGR4; MR-34a/mir-193a-3p-LGR4-αβ | LGR4 KO down-regulated progesterone signaling, affecting uterine receptivity and led to endometritis | Sone et al. (2013); Kida et al. (2014); An et al. (2017); de Oliveira et al. (2019); Ma et al. (2021); Yin et al. (2021) |
| Oviduct           | LGR4-WNT-NR5A2 signaling | The loss of LGR4 ultimately impaired the epithelial secretion | Tan et al. (2021) |

Elevated the expressions of integrinβ1, LGR4, LGR5, and LGR6, accompanied by triggering the Wnt/β-catenin pathway (Wang F. et al., 2020), thereby accelerating epithelialization in wound healing (Table 1 and Figure 3). Taken together, LGR4 was widely expressed in various tissues and played a fundamental role in modulating their development in a tissue-specific manner.

REGULATION OF LGR4 GENE IN IMMUNE-RELATED DISEASES

Cancer immunotherapy has demonstrated marvelous efficacy in clinical trials targeting negative immune checkpoint mediators including CTLA-4 and PD-1 (Pardoll, 2012). Tumor-associated macrophages (TAMs) constituted the major leukocytic infiltrate and could be polarized to a proinflammatory “M1” or an immunosuppressive “M2” phenotype by tumor-derived chemokines or cytokines (Mantovani et al., 2004). Tan, B. et al. demonstrated that Rspo-LGR4 axis functioned as a novel pathway aggravating M2-like macrophage polarization through noncanonical Erk/Stat3 signaling by recruiting IQGAP1 and MEK1/2, thus maintaining protumoral TAMs, promoting tumor progression and enhancing the resistance of Lewis lung carcinoma (LLC) cells to anti-PD1 treatment. Accordingly, LGR4 deficiency only in macrophages was able to activate both macrophage-mediated innate and T-cell-mediated adaptive antitumor immune responses, thus overcoming resistance to checkpoint blockade therapy, which gave this axis great potential as a promising therapeutic target in macrophage-targeting strategies (Tan et al., 2018). Moreover, LGR4 negatively modulated CD14 transcriptional activation and inhibited TLR2/4-associated immune response via cAMP-PKA-
CREB signaling (Du et al., 2013). Liu, S. et al. identified that LGR4 prevented intestinal inflammation by modulation of the Wnt/β-catenin signaling (Liu S. et al., 2013). Another study explored that the expression of LGR4 was reduced in traumatic osteoarthritis. Overexpression of LGR4 could suppress the joint inflammation by inhibiting NF-κB pathway (Ge et al., 2019). MiR-34a and miR-34c enhanced inflammatory response and delayed chronic wound healing of venous ulcers by direct targeting LGR4. MiR-34-LGR4 axis reduced GSK-3β-induced phosphorylation of p65 at Ser536, while enhancing phosphorylation at Ser536, activating NF-κB signaling, thus regulating inflammatory response of keratinocyte (Wu et al., 2020). Zhang, N. et al. showed that LGR4 functioned as a vesicular stomatitis virus (VSV)-specific host factor enhancing VSV infection, LGR4 knockdown reduced the levels of VSV (Zhang N. et al., 2017). Furthermore, LGR4 was related to the infection of severe acute respiratory syndrome coronavirus (SARS-CoV) (Liu H.-L. et al., 2020) (Table 2), and may be a potential gene target for therapy. Together these data pointed towards a key role for LGR4 in immune-related diseases, though further studies were needed to better establish this, especially in the field of tumor immunotherapy.

**TABLE 2 | The functions of LGR4 in immune-related diseases.**

| Diseases | Signaling | Effect | References |
|----------|-----------|--------|------------|
| Lung carcinoma associated macrophage | Rspo/LGR4/Erk/Stat3-enhanced macrophage M2 polarization | Blocking Rspo-LGR4 signaling overcame lung carcinoma resistance and suppressed tumor growth | Tan et al. (2018) |
| Macrophage in innate immunity | LGR4-cAMP-PKA-CREB signaling-CD14 | LGR4-deficiency led to increased immune response | Du et al. (2013) |
| Intestinal inflammation | LGR4-Wnt/β-catenin signaling | LGR4 (-/-) mice exhibited stronger intestinal inflammation | Liu et al. (2013b) |
| Traumatic osteoarthritis | LGR4-NF-κB signaling | Upregulation of LGR4 expression can inhibit the secretion of the inflammatory factors | Ge et al. (2019) |
| Keratinocyte in venous ulcers | MiR-34-LGR4-GSK-3β-induced p65 phosphorylation-NF-κB signaling | Knockout of LGR4 impaired wound closure with enhanced inflammation | Wu et al. (2020) |
| Vesicular stomatitis virus | Vesicular stomatitis virus-LGR4 | LGR4 knockdown suppressed VSV infection | Zhang et al. (2017b) |
THE ROLE OF LGR4 IN METABOLIC DISEASES

The expression of LGR4 was detected by in situ hybridization assay and was elevated in hypothalamic energy homeostatic areas and colocalized with some energy homeostatic neurons suggesting that it may regulate energy homeostasis (Van Schoore et al., 2005). In line with this, Otsuka, A. et al. showed that R-spondin1-LGR4 suppressed appetite of mice by upregulating Pomc gene expression. The suppressed food intake was not observed in LGR4 knockdown mice (Otsuka et al., 2019). Rspo1/Rspo3/LGR4 forming novel system to regulate feeding behavior (Li et al., 2014). Moreover, LGR4 ablation promoted the energy switch from glucose to fatty acid by activating Ampk/Sirt1/Pgc1α pathway (Sun et al., 2015). Importantly, the LGR4 A750T variant was investigated by Sanger sequencing, and the result found that it was correlated with central obesity (Zou et al., 2017). In addition, Shi et al. demonstrated that genetic polymorphisms of the LGR4 gene were related to bone and obesity phenotypes in Chinese nuclear families with female children (Shi et al., 2021). Furthermore, LGR4 was found to modulate energy balance and body weight through regulating the translation of white fat into brown fat (Wang J. et al., 2021). A recent study reported that Rspo1/LGR4 axis was involved in obesity-related renal fibrosis through promoting Wnt/β-catenin signaling pathway, providing a potential therapeutic target for the obesity-related chronic kidney disease (CKD) (Su et al., 2021). Likewise, LGR4, as a adipocytokine, was closely related to the progression of diabetes and hypertension (Li B. et al., 2019). Notably, Wang, J. et al. identified that LGR4 elevated mineralocorticoid receptor (MR) expression by cAMP/protein kinase A pathway to improve aldosterone responsiveness and maintain electrolyte homeostasis (Wang et al., 2012). Meanwhile, Rspo1/Rspo3-LGR4 signaling attenuated cholesterol synthesis in hepatocytes by activating the phosphorylation of AMPKα and suppressing SREBP2 nuclear translocation (Liu S. et al., 2020). Hence, the function of LGR4 in energy metabolism was being broadly studied, a better understanding of the molecular mechanism underlying various metabolic pathways involved by LGR4 will help in future development of new treatments for metabolic diseases.

THE ROLE OF LGR4 IN OXIDATIVE STRESS DAMAGE

Oxidative stress exerted an increased impact on pathophysiology of osteoporosis. However, the correlation between LGR4 and oxidative stress remained unknown. Pawaputanon Na et al. explored that the treatment of hydrogen peroxide decreased the expression of LGR4 in osteoblastic cells (Pawaputanon Na Mahasarakham et al., 2017). Rspo1-LGR4 axis protected hepatocytes against acute injury by suppressing NF-kB-p65 via Wnt3a/β-catenin pathway (Li Z. et al., 2019). Of note, Liu, S. et al. reported that Rspo3-LGR4 system protected hepatocytes from dimethyloxalylglycine (DMOG)-caused hypoxia/reoxygenation (H/R) damage by Wnt3a/β-catenin pathway (Liu et al., 2018). LGR4 also controlled mitochondrial function and oxidative stress by activating ERK signaling, thus protecting myocardium against ischemia-reperfusion (I/R) damage (Chen T. et al., 2021). Additionally, Singla, B. et al. showed that RSPO2-LGR4 interaction reduced lymphangiogenesis by inhibiting PI3K-AKT-eNOS and Wnt-β-catenin pathway. LGR4 silencing could block this process and facilitate cholesterol drainage from atherosclerotic arteries (Singla et al., 2020). Conversely, Huang, C. K. et al. showed that LGR4 could induce proinflammatory responses in myocardial infarction (MI) by elevating the expression of AP-1 via CREB-regulated c-Fos, Fosl1, and Fosb activation. Knockout of LGR4 could mitigate ischemic injury (Huang et al., 2020). Study uncovered that radiation therapy elevated the expression of Rspo1 and LGR4 in bone mesenchymal stem cells (BMSCs). Exogenous Rspo1 reduced radiation-induced bone damage by Rspo1-LGR4-mTOR-autophagy signaling (Chen X. et al., 2021) (Table 4). Therefore, LGR4 was involved in oxidative stress and cellular damage, a deeper exploration of its mechanisms was still required. From a broader and longer-term perspective, these investigations may slow or even reverse the onset of stress injuries by targeting LGR4 gene.

| Pathway | Effect | References |
|---------|--------|------------|
| LGR4-cAMP/PKA | LGR4 KO mice had aldosterone resistance | Wang et al. (2012) |
| Rspo1/Rspo3/LGR4 | Injection of Rspo1 or Rspo3 inhibited food intake | Li et al. (2014) |
| R-spondin1-LGR4-Pomc | LGR4 KO mice didn’t exhibit a suppressed appetite | Otsuka et al. (2019) |
| LGR4-Ampk/Sirt1/Pgc1α pathway | LGR4 ablation enhanced fuel shift | Sun et al. (2015) |
| Rspo1/Rspo3-LGR4-AMPKa-SREBP2 pathway | Rspo1/Rspo3-LGR4 signaling suppresses cholesterol synthesis | Liu et al. (2020b) |

SUGGESTED ROLES OF LGR4 IN CARCINOMAS

The gene of LGR4 emerged as a critical player in regulation of tumor growth and progression (Gong et al., 2015; Liang et al., 2015). Zhu, Y. B. et al. identified that LGR4 induced Wnt/β-catenin signaling to promote cancer cell growth and migration (Zhu et al., 2013). Accordingly, Kang, Y. E. et al. demonstrated that R-spondin 2 and LGR4 were overexpressed in thyroid cancer. The upregulated LGR4 enhanced cell proliferation and migration by inducing the phosphorylation of ERK and GSK3β and activating β-catenin pathway (Kang et al., 2017). The expression of LGR4 was elevated after prostate cancer radiotherapy. LGR4 ablation inhibited AR/CREB1 expression, promoted yH2A.X staining and reduced tumor growth (Liang et al., 2015).
et al., 2021). Moreover, LGR4 was overexpressed in human prostate cancer and correlated with shorter disease-free survival. The knockdown of LGR4 inhibited cell migration and reversed EMT by elevating the expression of E-cadherin (Luo et al., 2017). Also, Zhang, J. et al. revealed that LGR4 promoted Jmjd2a/AR signaling to enhance AR binding to PSA promoter, thus contributing to inducing prostate tumorigenesis (Zhang et al., 2016). LGR4 may also facilitate the growth of prostate cancer via the PI3K/Akt/mTOR signaling (Liang et al., 2015). LGR4 may also facilitate the growth of prostate cancer via the PI3K/Akt/mTOR signaling (Liang et al., 2015). Additionally, LncGata6 recruited the NURF complex onto the promoter of Ehf to enhance its transcription, which elevated the expression of LGR4/5 to activate Wnt signaling, thus promoting the progression of colorectal cancer (Zhu et al., 2018). Wang, Y. et al. showed that the expression of LGR4 was elevated in uveal melanoma cells. MiR-34a negatively controlled the expression level of LGR4, thus downregulating the markers of the EMT and MMP2, thereby impacting the aggressiveness of uveal melanoma (Hou et al., 2019). Study reported that LGR4 was considered as an independent prognostic marker for patients with non-small cell lung cancer (NSCLC) (Li R. et al., 2020). MiR-449b as a tumor suppressor prevented the proliferation of NSCLC by downregulating LGR4 (Yang et al., 2018) and LGR4 was perceived as a high-risk immune gene in NSCLC (Sun et al., 2020). The aberrant activation of RSPO3-LGR4-IQGAP1 system promoted tumor aggressiveness in Keap1-deficient lung adenocarcinomas. Knockdown of LGR4 led to reduction in cell proliferation (Gong et al., 2015). Additionally, Zhang, L. et al. showed that Rspon2-LGR4 system promoted the growth and migration of tongue squamous cell carcinoma (TSCC). It potentiared β-catenin pathway by enhancing phosphorylation of LRP6, while reducing phosphorylation of GSK-3β, contributing to subsequent upregulation of TCF-1 and its downstream genes CD44, c-Myc, and Cyclin D1, thus facilitating the progression of TSCC (Zhang et al., 2019). LGR4 could also promote the proliferation of gloma by activating Wnt/β-catenin signaling (Yu et al., 2013). Stat3 could elevate LGR4 expression by binding to LGR4 promoter, thereby regulating osteosarcoma progression (Liu J. et al., 2013). Furthermore, van Andel, H. et al. identified that R-spondin/LGR4 axis promoted multiple myeloma (MM) by activating aberrant Wnt/β-catenin signaling (van Andel et al., 2017). LGR4 acted as an essential positive factor for inducing skin tumorigenesis by activating MEK1/ERK1/2/AP-1 and Wnt/β-catenin pathways (Xu et al., 2016). Conversely, Souza, S. M. et al. detected that LGR4 was expressed in a larger number of cells in normal gastric mucosa than in primary gastric carcinomas and not specific to gastric cancer cells, predominantly affecting the expression of β-catenin in membrane-complex but rarely in nucleus, suggesting a controversial function of LGR4, and which was positively correlated with cell proliferation but inversely related to cancer progression (Souza et al., 2019) (Table 5 and Figure 4). Due to various carcinogenic factors, multiple cellular microenvironment and a variety of cell types, the complicated functions of LGR4 in

### Table 4: Increased impacts of LGR4 gene on oxidative stress response.

| Pathway | Effect | References |
|---------|--------|------------|
| Rsps1-LGR4-Wnt3a/β-catenin-NF-κB-p65 | LGR4 protected hepatocytes from injury | Liu et al. (2018); Li et al. (2019b) |
| LGR4-ERK signaling-oxidative stress | LGR4 protected cardiomyocyte against I/R | Chen et al. (2021a) |
| RSPO2-LGR4-Pi3K-akt/Eno/Wnt-β-catenin | LGR4 silencing promoted lymphangiogenesis | Sinha et al. (2020) |
| LGR4-CREB-mediated c-Fos/Fosb/Fosb/AP-1 | LGR4 knockout infarcts had reduced inflammatory | Huang et al. (2020) |
| Rsps1-LGR4-mTOR-autophagy | Exogenous Rsps1-LGR4 alleviated radiation-induced bone loss | Chen et al. (2021b) |

**Table 5** | **Increased impacts of LGR4 gene on oxidative stress response.**

| Pathway | Effect | References |
|---------|--------|------------|
| Rsps1-LGR4-Wnt3a/β-catenin-NF-κB-p65 | LGR4 protected hepatocytes from injury | Liu et al. (2018); Li et al. (2019b) |
| LGR4-ERK signaling-oxidative stress | LGR4 protected cardiomyocyte against I/R | Chen et al. (2021a) |
| RSPO2-LGR4-Pi3K-akt/Eno/Wnt-β-catenin | LGR4 silencing promoted lymphangiogenesis | Sinha et al. (2020) |
| LGR4-CREB-mediated c-Fos/Fosb/Fosb/AP-1 | LGR4 knockout infarcts had reduced inflammatory | Huang et al. (2020) |
| Rsps1-LGR4-mTOR-autophagy | Exogenous Rsps1-LGR4 alleviated radiation-induced bone loss | Chen et al. (2021b) |
## TABLE 5 | The gene of LGR4 involving in the process of multiple tumors.

| Cancer subtypes          | Pathway                                      | Effect                                         | References                                  |
|--------------------------|----------------------------------------------|-----------------------------------------------|---------------------------------------------|
| Skin carcinoma           | LGR4-MEK1/ERK1/2/AP-1 and Wnt/j-catenin pathways | LGR4 was crucial for skin carcinogenesis | Xu et al. (2016)                           |
| Glioma                   | LGR4-Wnt/j-catenin                           | LGR4 overexpression promoted cell proliferation | Yu et al. (2013)                           |
| Uveal melanoma           | MI3-34a-LGR4-MMP2                            | Knockdown of LGR4 attenuated the aggressiveness | Hou et al. (2019)                           |
| Tongue carcinoma         | Rsps2-LGR4-Wnt/j-catenin                     | Elevated LGR4 promoted growth                 | Zhang et al. (2019)                        |
| Thyroid carcinomas       | R-spondin2-LGR4-p-ERK-p-LRP6-p-GSK3jl-j-catenin | Elevated expression of LGR4 promoted proliferation and migration | Kang et al. (2017)                        |
| Lung cancer              | RSPC3-LGR4- IQGAP1, Mir-449b-LGR4             | Knockdown of LGR4 decreased tumor growth      | Gao et al. (2006); Wu et al. (2013); Zhu et al. (2018); Zhi et al. (2019) |
| Colon cancer             | p27Kip1-LGR4, CircLGR4-LGR4-Wnt/j-catenin, LGR4-GSK3jl-p9K/Akt-MAPK-ERK1/2-catenin/TCF-Cyclin-D1/c-Myc, LncGata6-NJURF-Ehf-LGR4/S-Wnt | LGR4 expression was associated with colorectal tumorigenesis | Gao et al. (2006); Wu et al. (2013); Zhu et al. (2018); Zhi et al. (2019) |
| Acute myeloid leukemia   | RSPC3-LGR4-HOXA9                             | RSPC3-LGR4 interaction promoted proliferation | Salik et al. (2020)                         |
| Multiple myeloma         | IL-6/STAT3-LGR4/R-spondin- Wnt/j-catenin     | LGR4 expression was driven by IL-6/STAT3 signaling and allowed MM cells to hijack R-spondins | van Andel et al. (2017)                    |
| Osteosarcoma             | Stat3-LGR4                                   | Overexpression of Stat3 promoted LGR4 expression | Liu et al. (2013a)                         |
| Breast cancer            | LGR4- Wnt/j-catenin signaling, LGR4-EGFR signaling | LGR4 down-regulation decreased tumor growth and lung metastasis | Zhu et al. (2013); Yue et al. (2018); Yue et al. (2021) |
| Prostate cancer          | LGR4-EMT, LGR4-Jmjd2a/AR signaling-PSA, Mir-137-LGR4-EGFR/ERK, LGR4-AR/CREB1 expression, LGR4-P9K/Akt/mTOR | LGR4 knockdown impaired cell migration | Liang et al. (2015); Zhang et al. (2018); Luo et al. (2017); Zhang et al. (2020); Liang et al. (2021) |
| Ovarian cancer           | WNT7B/Fzd5-LGR4/ELF3 axis                    | LGR4 overexpression enhanced tumorosphere formation capacity | Wang et al. (2020c)                        |
| Cervical cancer          | XISt/LGR4, XISt/mR-23a-3p/LGR4               | —                                             | Berti et al. (2021)                        |

## FIGURE 4 | The cross-talking of LGR4 with other molecules in multiple carcinomas. Several studies indicated that LGR4 was overexpressed in cancer tissues. The molecules including circLGR4, IncGata6-NJURF-Ehf, XISt/mR-23a-3p, miR-137, miR-449b, miR-34a, IL-6/STAT3, p27Kip1, WNT7B/Fzd5, and RSPC2/3 could function as upstream regulators of LGR4 and mediate its expression. Then, LGR4 could modulate the proteins such as IQGAP1, ELF3, MMP2, and HOXA9 to control tumor progression and trigger the Wnt/j-catenin, MEK1/ERK1/2/AP-1, P9K/Akt pathways to promote the initiation and metastasis of a variety of malignancies.
carcinogenesis needed further exploration. Therefore, given the multitude of indications for the relevant oncogenic role of LGR4, it remained valuable to further investigate the clinical potential of anti-LGR4 monoclonal antibodies specifically in cancer patients that harbored LGR4 alterations, which would hopefully provide more insight beneficial to the development of novel treatment strategies against LGR4 driven cancer.

DISCUSSION AND FUTURE DIRECTIONS

In general, a growing body of evidence indicated that LGR4 was widely expressed in diverse tissues from the early embryogenesis to adulthood, participated in the differentiation and development of various organs, involved in immune-related diseases, metabolic diseases as well as oxidative stress damage and contributed to multiple cancer progression. The repertoire of the physiological and pathological roles of LGR4 in numerous cellular processes provided a systematic and comprehensive understanding of its functional characteristics, thereby offering a novel diagnostic biomarker and therapeutic target for a range of diseases.

The interaction between LGR4 and its ligands including RSPOs, Norrin, RANKL, and could activate the downstream Wnt pathway and other G protein-associated pathways. Several researches implicated that inhibitors or antagonists of the RSPOs/LGR4/Wnt/β-catenin axis could suppress tumor metastasis and recurrence. Moreover, blockage of the LGR4 signaling would result in a decreased population and impaired migration ability of cancer stem cells, which may lay a solid theoretical basis for the development of small molecule blockers and antagonizing antibodies to suppress LGR4 pathway.

Additionally, with regard to the LGR4/cAMP/PKA signaling, the endogenous ligands that activated LGR4 were yet to be elucidated clearly. Meanwhile, the function of LGR4 through its newly discovered ligand RANKL was mainly detected in maintaining homeostasis of bone tissue, whereas their involvement in malignancies was rarely explored. Hence, further detailed mechanism investigation was crucial for representing the spatiotemporal profile of LGR4 and might open up a new avenue for molecular targeted therapy for tumors and other diseases.

AUTHOR CONTRIBUTIONS

LY designed and wrote this paper. JW, XG, and QF participated in literature searching and sorting. XY, YC, XG, LL, and XS analyzed the data, YL and YW assessed and edited this work. All authors have read and approved the final version of the manuscript.

FUNDING

This work was funded by Shanghai Municipal Key Clinical Specialty (No. shlslczdjk06302), National Natural Science Foundation of China (No. 81172477, 81402135), the Project of the Science and Technology Commission of Shanghai Municipality (No. 17441907400), and Shanghai Jiao Tong University Medicine-Engineering Fund (No. YG2017MS41).

ACKNOWLEDGMENTS

The authors wish to thank the International Peace Maternity and Child Health Hospital for the excellent scientific research platform.

REFERENCES

An, X., Liu, X., Zhang, L., Liu, J., Zhao, X., Chen, K., et al. (2017). MiR-449a Regulates Caprine Endometrial Stromal Cell Apoptosis and Endometrial Receptivity. Sci. Rep. 7 (1), 12248. doi:10.1038/s41598-017-12451-y

Arima, M., Hasegawa, D., Yoshida, S., Mitarai, H., Tomokiyou, A., Hamano, S., et al. (2019). R-spondin 2 Promotes Osteoelastic Differentiation of Immature Human Periodontal Ligament Cells through the Wnt/β-Catenin Signaling Pathway. J. Periodontol. Res. 54 (2), 143–153. doi:10.1111/jpr.12611

Barker, N., Tan, S., and Clevers, H. (2013). Lgr Proteins in Epithelial Stem Cell Biology. Development 140 (12), 2484–2494. doi:10.1242/dev.083113

Berti, F. C. B., Mathias, C., Garcia, L. E., Gradia, D. F., de Araújo-Souza, P. S., Chipolla, G. A., et al. (2021). Comprehensive Analysis of ceRNA Networks in HPV16- and HPV18-Mediated Cervical Cancers Reveals XIST as a Pivotal Receptivity. Biochim. Biophys. Acta (Bba) - Mol. Basis Dis. 1867, 166172. doi:10.1016/j.bbadis.2021.166172

Carmon, K. S., Gong, X., Lin, Q., Thomas, A., and Liu, Q. (2011). R-spondin Functions as Ligands of the Orphan Receptors LGR4 and LGR5 to Regulate Wnt/β-catenin Signaling. Proc. Natl. Acad. Sci. 108 (28), 11452–11457. doi:10.1073/pnas.1106083108

Carmon, K. S., Gong, X., Yi, J., Thomas, A., and Liu, Q. (2014). RSPO-LGR4 Functions via IQGAP1 to Potentiate Wnt Signaling. Proc. Natl. Acad. Sci. USA 111 (13), E1221–E1229. doi:10.1073/pnas.1323106111

Carrillo-López, N., Martínez-Arias, L., Alonso-Montes, C., Martín-Carro, B., Martín-Virgala, J., Ruiz-Ortega, M., et al. (2020). The Receptor Activator of Nuclear Factor κB Ligand Receptor Leucine-Rich Repeat-Containing G-Protein-Coupled Receptor 4 Contributes to Parathyroid Hormone-Induced Vascular Calcification. Nephrol. Dial. Transpl. 36, 618–631. doi:10.1093/ndt/gfz290

Chauhan, G., Mehta, A., and Gupta, S. (2020). Stromal-AR Influences the Growth of Epithelial Cells in the Development of Benign Prostate Hyperplasia. Mol. Cell Biochem. 471 (1–2), 129–142. doi:10.1007/s11010-020-03773-z

Chen, T., Qiao, X., Cheng, L., Liu, M., Deng, Y., and Zhuo, X. (2021a). LGR4 Silence Aggravates Ischemic Injury by Modulating Mitochondrial Function and Oxidative Stress via ERK Signaling Pathway in H9c2 Cells. J. Mol. Histol. 52, 363–371. doi:10.1007/s10735-021-09957-1

Chen, X., Chen, L., Tan, J., Zhang, L., Xia, J., Cheng, B., et al. (2021b). Rspo1-LGR4 Axis in BMSCs Protects Bone against Radiation-induced Injury through the mTOR-dependent Autophagy Pathway. J. Cell Physiol 256, 4273–4289. doi:10.1002/jcp.30051

Cong, F., Wu, N., Tian, X., Fan, J., Liu, J., Song, T., et al. (2017). MicroRNA-34c Promotes Osteoclast Differentiation through Targeting LGR4. Gene 610, 1–8. doi:10.1016/j.gene.2017.01.028

Da Silva, F., Massa, F., Motamedi, F. J., Vidal, V., Rocha, A. S., Gregoire, E. P., et al. (2018). Myocardial-specific R-Spondin3 Drives Proliferation of the Coronary Stems Primarily through the Leucine Rich Repeat G Protein Coupled Receptor LGR4. Dev. Biol. 441 (1), 42–51. doi:10.1016/j.ydbio.2018.05.024

Dang, Y., Liu, B., Xu, P., Zhu, P., Zhai, Y., Liu, M., et al. (2014). Gpr48 Deficiency Induces Polycystic Kidney Lesions and Renal Fibrosis in Mice by Activating Wnt Signal Pathway. PLoS One 9 (3), e89835. doi:10.1371/journal.pone.0089835
Jin, C., Yin, F., Lin, M., Li, H., Wang, Z., Weng, J., et al. (2008). GRPR4 Regulates Epithelial Cell Proliferation and Migration by Activating EGFR during Eyelid Development. *Invest. Ophthalmol. Vis. Sci.* 49 (10), 4245–4253. doi:10.1167/iovs.08-1860

Jin, Y.-R., Han, X. H., Nishimori, K., Ben-Avraham, D., Oh, Y. J., Shim, J.-w., et al. (2020). Canonical WNT/β-Catenin Signaling Activated by WNT9b and RSPO2 Cooperation Regulates Fetal Morphogenesis in Mice. *Front. Cell Dev. Biol.* 8, 264. doi:10.3389/fceld.2020.00264

Kajava, A. V. (1998). Structural Diversity of Leucine-Rich Repeat Proteins 1 Edited by F. Cohen. *J. Mol. Biol.* 277 (3), 519–527. doi:10.1006/jmbi.1998.1643

Kang, Y. E., Kim, J.-M., Kim, K. S., Chang, J. Y., Jung, M., Lee, J., et al. (2017). Upregulation of RSPO2-Gpr48 Signaling in Papillary Thyroid Carcinoma Contributes to Tumor Progression. *Oncotarget* 8 (70), 114980–114994. doi:10.18632/oncotarget.22692

Kato, S., Matusbara, M., Matsu, T., Mohri, Y., Kazama, I., Hatanio, R., et al. (2006). Leucine-rich-repeat-containing G Protein-Coupled Receptor 4 (LGR4, GPR48) Is Essential for Renal Development in Mice. *Nephron Exp. Nephrol.* 104 (2), e6–e7. doi:10.1159/000093999

Kato, S., Mohri, Y., Matsu, T., Ogawa, E., Umezawa, A., Okuyama, R., et al. (2007). Eye-open at Birth Phenotype with Reduced Keratocyste Motility in LGR4 Null Mice. FERS Lett. 581 (24), 4685–4690. doi:10.1063/jfb.2007.08.064

Kida, T., Oyama, K., Sone, M., Kozumi, M., Hidema, S., and Nishimori, K. (2014). Lgr4 Is Required for Endometrial Recetivity Acquired through Ovarian Hormone Signaling. *Biosci. Biotechnol. Biochem.* 78 (11), 1813–1816. doi:10.2639/bibs.2014.136353

Kim, H. S., Kim, Y. S., Lee, C., Shin, M. S., Kim, J. W., and Jang, B. G. (2019). Expression Profile of Sonic Hedgehog-Signaling-Related Molecules in Basal Cell Carcinoma. *PLoS One* 14 (11), e0225511. doi:10.1371/journal.pone.0225511

Knight, M. N., and Hankenson, K. D. (2014). R-spondins: Novel Macrorticel Regulators of the Skeleton. *Matrix Biol.* 37, 157–161. doi:10.1016/j.mabio.2014.06.003

Ko, Y. J., Sohn, H. M., Jang, Y., Park, M., Kim, B., Kim, B., et al. (2021). A Novel Modified RANKL Variant Can Prevent Osteoporosis by Acting as a Vaccine and an Inhibitor. *Clin. Translational Med.* 11 (3), e368. doi:10.1002/ctm2.368

Kobe, B., and Deisenhofer, J. (1995). A Structural Basis of the Interactions between Leucine-Rich Receptors and Protein Ligands. *Nature* 374 (6518), 183–186. doi:10.1038/374183a0

Kobe, B., and Deisenhofer, J. (1993). Crystal Structure of Porcine Ribonuclease Inhibitor, a Protein with Leucine-Rich Repeats. *Nature* 366 (6457), 751–756. doi:10.1038/366751a0

Kozumi, M., Oyama, K., Yamakami, Y., Kida, T., Satoh, R., Kato, S., et al. (2015). Lgr4 Controls Specialization of Female Gonads in Mice1. *Biol. Reprod.* 93 (4), 90. doi:10.1095/biolreprod.114.123638

Koo, B.-K., Spirt, M., Jordens, I., Low, Y. T., Stange, D. E., van de Wetering, M., et al. (2012). Tumour Suppressor RNF43 Is a Stem-Cell E3 Ligase that Induces Endocytosis of Wnt Receptors. *Nature* 488 (7413), 665–669. doi:10.1038/nature11308

Lai, S., Cheng, R., Gao, D., Chen, Y. G., and Deng, C. (2020). LGR5 Constitutively Activates NF-κB Signaling to Regulate the Growth of Intestinal Cysts. *FASEBJ.* 34 (11), 15605–15620. doi:10.1096/fasebj.34.11.202001329R

Li, B., Yao, Q., Guo, S., Ma, S., Dong, Y., Xin, H., et al. (2019a). Type 2 Diabetes with Hypertensive Patients Results in Changes to Features of Adipocytokines: Leptin, Irisin, LGR4, and Sfrp5. *Clin. Exp. Hypertens.* 41 (7), 645–650. doi:10.1080/03621334.2018.1529779

Li, C., Huang, Q., Yang, R., Guo, D., Dai, Y., Zeng, J., et al. (2020a). Targeted Next Generation Sequencing of Nine Osteoporosis-Related Genes in the Wnt Signaling Pathway Among Chinese Postmenopausal Women. *Endocrine* 68 (3), 669–678. doi:10.1007/s12020-020-02248-x

Li, J.-Y., Chai, B., Zhang, W., Fritze, D. M., Zhang, C., and Mulholland, M. W. (2014). LGR4 and its Ligands, R-Spondin 1 and R-Spondin 3, Regulate Food Intake in the Hypothalamus of Male Rats. *Endocrinology* 155 (2), 429–440. doi:10.1210/en.2013-1550

Li, R., Liu, X., Zhou, X. J., Chen, X., Li, J. P., Yin, Y. H., et al. (2020b). Identification and Validation of the Prognostic Value of Immune-Related Genes in Non-small Cell Lung Cancer. *Am. J. Transl. Res.* 12 (9), 5844–5865

Li, X.-Y., Lu, Y., Sun, H.-Y., Yang, J.-Q., Yang, J., Zhang, H.-J., et al. (2010). G Protein-Coupled Receptor 48 Upregulates Estrogen Receptor α Expression via...
Liu, S., Qian, Y., Li, L., Wei, G., Guan, Y., Pan, H., et al. (2013b). LGR4 Gene
Liu, S., Yin, Y., Yu, R., Li, Y., and Zhang, W. (2018). R-spondin3-LGR4 Signaling
Luo, C. W., and Hsueh, A. J. (2006). Genomic Analyses of the Evolution of LGR
Liu, S., Gao, Y., Zhang, L., Yin, Y., and Zhang, W. (2020b). Rspo1/Rspo3-LGR4 Signaling Enhances Radiation Sensitivity of Prostate Cancer Cells. J. Biol. Chem. 295 (18), 18133–18142. doi:10.1074/jbc.RA120.005848
Luo, W., Rodriguez, M., Valdez, J. M., Zhu, X., Tan, K., Li, D., et al. (2013). Lgr4 Is a Key Regulator of Prostate Development and Prostate Stem Cell Differentiation. Stem Cells 31 (11), 2499–2505. doi:10.1002/stem.1484
Luo, W., Tan, P., Rodrigues, M., He, L., Tan, K., Zeng, L., et al. (2017). Leucine-rich Repeat-Containing G Protein-Coupled Receptor 4 (Lgr4) Is Necessary for Prostatic Cancer Metastasis via Epithelial-Mesenchymal Transition. J. Biol. Chem. 292 (37), 15525–15537. doi:10.1074/jbc.M116.771931
Ma, X., Yin, B., Guo, S., Umar, T., Liu, J., Wu, Z., et al. (2021). Enhanced Expression of miR-34a Enhances Escherichia coli Lipopolysaccharide-Mediated Endothritis by Targeting LGR4 to Activate the NF-κB Pathway. Oxidative Med. Cell Longevity 2021, 1–18. doi:10.1155/2021/1744754
Mancini, A., Howard, S. R., Marelli, F., Cabrera, C. P., Barnes, M. R., Sternberg, J. J., et al. (2020). LGR4 Deficiency Results in Delayed Puberty through Impaired Wnt/β-Catenin Signaling. JCI Insight 5 (11). doi:10.1172/jci.insight.133434
Mantovani, A., Sica, A., Sozzani, S., Allavena, P., Vecchi, A., and Locati, M. (2004). The Chemokine System in Diverse Forms of Macrophage Activation and Polarization. Trends Immunol. 25 (12), 677–686. doi:10.1016/j.it.2004.09.015
Matsukie, R., Tanaka, H., Nakai, K., Kanda, M., Nagasaki, M., Murakami, F., et al. (2018). Continuous Application of Compensatory Force Induces Fusion of Osteostat-like RAW264.7 Cells via Uprogelation of RANK and Downregulation of LGR4. Life Sci. 201, 30–36. doi:10.1016/j.lfs.2018.03.038
Mazoyer, S., Bouley, D. M., Sudo, S., Klein, C. A., Zhang, J. V., Kawamura, K., et al. (2004). Leucine-rich Repeat-Repeating G Protein-Coupled Receptor 4 Null Mice Exhibit Intratraheal Growth Retardation Associated with Embryonic and Perinatal Lethality. Mol. Endocrinol. 18 (9), 2241–2254. doi:10.1210/me.2004-0113
McDonald, T., Wang, R., Bailey, W., Xie, G., Chen, F., Caskey, C. T., et al. (1998). Identification and Cloning of an Orphan G Protein-Coupled Receptor of the Glycoprotein Hormone Receptor Subfamily. Biochem. Biophys. Res. Commun. 247 (2), 266–270. doi:10.1006/bbrc.1998.8774
Mendive, F., Laurent, P., Van Schoore, G., Skarnes, W., Pochet, R., and Vassart, G. (2006). Defective Postnatal Development of the Male Reproductive Tract in LGR4 Knockout Mice. Dev. Biol. 290 (2), 421–434. doi:10.1016/j.ydbio.2005.11.043
Mustata, R. C., Van Loy, T., Lefort, A., Libert, F., Strollo, S., Vassart, G., et al. (2011). Lgr4 Is Required for Paneth Cell Differentiation and Maintenance of Intestinal Stem Cells Ex Vivo. EMBO Rep. 12 (6), 558–564. doi:10.1038/embor.2011.52
Naka, K., Ochiai, R., Matusbara, E., Kondo, C., Yang, K.-M., Hoshii, T., et al. (2020). The Lysophospholipase D Enzyme Gpdp3 Is Required to Maintain Chronic Myologenous Leukaemia Stem Cells. Nat. Commun. 11 (1), 4681. doi:10.1038/s41467-020-18491-9
Oliveira, V., Schaefer, J., Calder, M., Lydon, J. P., DeMayo, F. J., Bhattacharyya, M., et al. (2019). Uterine Gα11 Signaling, in a Progestrone-dependent Manner, Critically Regulates the Acquisition of Uterine Receptivity in the Female Mouse. FASEB J. 33 (8), 9374–9387. doi:10.1096/fj.201900263R
Otsuka, A., Jingui, A., Majeima, Y., Kasahara, Y., Shimomura, K., Hidema, S., et al. (2019). LGR4 Is Essential for R-Spondin1-Mediated Suppression of Food Intake via Pro-opiomelanocortin. Biochim. Biophys. Acta. 83 (7), 1336–1342. doi:10.1016/j.bjba.2019.159126
Pan, H., Cui, H., Liu, Si, Qian, Y., Wu, H., Li, L., et al. (2014). Lgr4 Gene Regulates Corpus Luteum Maturation through Modulation of the WNT-Mediated EGFR-ERK Signaling Pathway. Endocrinology 155 (9), 3624–3637. doi:10.1210/en.2013-2183
Pardoll, D. M. (2012). The Blockade of Immune Checkpoints in Cancer Immunotherapy. Nat. Rev. Cancer 12 (4), 252–264. doi:10.1038/nrc3239
Park, S., Cui, J., Wu, W., Lu, M., Lin, X., and Li, Q. J. (2018). Differential Activities and Mechanisms of the Four R-Spondins in Potentiating Wnt/β-Catenin Signaling. J. Biol. Chem. 293 (25), 9759–9769. doi:10.1074/jbc.RA118.011274
Park, S., Wu, L., Lu, J., Wu, Y., Toh, Y., Yam, K.-S., et al. (2020). Unlike LGR4, LGR5 Potentiates Wnt/β-Catenin Signaling without Sequestering E3 Ligases. Sci. Signal. 13 (660). doi:10.1126/scisignal.aaz4051
Pawpatuwan Na Mahasarakham, C., Izuz, Y., Nishimori, K., Izumi, Y., Noda, M., and Ezura, Y. (2017). Lgr4 Expression in Osteoblastic Cells Is Suppressed by Hydrogen Peroxide Treatment. J. Cell. Physiol. 232 (7), 1761–1767. doi:10.1002/jcp.25684
Planas-Paz, L., Orsini, S., Boulter, D., Calabrese, D., Pikiolek, M., Nishg, F., et al. (2016). The RSPO-Lgr4/5-Znrf3/rnf43 Module Controls Liver Zonation and Bile Formation via Pro-opiomelanocortin. Biochim. Biophys. Acta. 83 (7), 1766. doi:10.1016/j.bjba.2016.03.037
Planas-Paz, L., Sun, T., Pikiolek, M., Cochran, N. R., Bergling, S., Orsini, V., et al. (2019). YAP, but Not RSPO-Lgr4/5, Signaling in Biliary Epithelial Cells Promotes a Ductular Reaction in Response to Liver Injury. Cell Stem Cell 25 (1), 39–53. doi:10.1016/j.stem.2019.04.005
Ren, X., Xia, W., Xu, P., Shen, H., Dai, X., Liu, M., et al. (2020). Lgr4 Deletion Delays the Hair Cycle and Inhibits the Activation of Hair Follicle Stem Cells. J. Invest. Dermatol. 140 (9), 1706e1704–1712. doi:10.1111/jid.2019.12.034
Salk, B., Ti, H., Hassan, N., Santtiapillai, N., Vick, B., Connerty, P., et al. (2020). Targeting RSPO3-LGR4 Signaling for Leukemia Stem Cell Eradication in Acute Myloid Leukemia. Cancer Cell 38 (2), 263–278. doi:10.1016/j.ccell.2020.05.014
Schoore, G. V., Mendive, F., Pochet, R., and Vassart, G. (2005). Expression Pattern of the Orphan Receptor LGR4/GP48 Gene in the Mouse. Histochim. Cell Biol. 124 (1), 35–50. doi:10.1007/s00418-005-0002-3
Shi, G.-X., Zheng, X.-F., Zhu, C., Li, B., Wang, Y.-R., Jiang, S.-D., et al. (2017). Continuous Application of Compressive Force Induces Fusion of Myeloid Leukemia Cells. Sci. Transl. Med. 9 (404). doi:10.1126/scitranslmed.aaj2735
Singla, B., Lin, H.-P., Chen, A., Ahn, W., Ghosal, P., Cherian-Shaw, M., et al. (2020). Role of R-Spondin 2 in Arterial Lymphangiogenesis and Atherosclerosis. Cardiovasc. Res. 117, 1489–1509. doi:10.1093/cvr/cva224
Yang et al. LGR4 in Diseases and Carcinomas

Zeng, Z., Ji, N., Yi, J., Lv, J., Yuan, J., Lin, Z., et al. (2020). LGR4 Overexpression Is Associated with Clinical Parameters and Poor Prognosis of Serous Ovarian Cancer. *Cancer Res.* 81 (17), 4441–4454. doi:10.1158/0008-5472.Can-21-1112

Yue, Z., Yuan, Z., Zeng, L., Wang, Y., Lai, L., Li, J., et al. (2018). LGR4 Modulates Hypoxia-mediated Migration and Epithelial-mesenchymal Transition in Prostate Cancer by Targeting LGR4 via the EGFR/ERK Signaling Pathway. *Int. J. Oncol.* 53 (2), 540–549. doi:10.3892/ijo.2020.5064

Zhang, J., Li, Q., Zhang, S., Xu, Q., and Wang, T. (2016). Lgr4 Promotes Prostate Tumorigenesis through the Jmj2a/AR Signaling Pathway. *Exp. Cell Res.* 349 (1), 77–84. doi:10.1016/j.yexcr.2016.09.023

Zhang, L., Song, Y., Ling, Z., Li, Y., Ren, X., Yang, J., et al. (2019). R-spondin 2-LGR4 System Regulates Growth, Migration and Invasion, Epithelial-mesenchymal Transition and Stem-like Properties of Tongue Squamous Cell Carcinoma via Wnt/β-Catenin Signaling. *EBioMedicine* 44, 275–288. doi:10.1016/j.ebiom.2019.03.076

Zhang, M., Zhang, P., Liu, Y., Lv, L., Zhang, X., Liu, H., et al. (2017a). RSPO3-LGR4 Regulates Osteogenic Differentiation of Human Adipose-Derived Stem Cells via ERK/FGF Signalling. *Sci. Rep.* 7, 42841. doi:10.1038/srep42841

Zhang, N., Huang, H., Tan, B., Wei, Y., Xiong, Q., Yan, Y., et al. (2017b). Leucine-rich Repeat-Containing G Protein-Coupled Receptor 4 Facilitates Vascular Stomatitis Virus Infection by Binding Vascular Stomatitis Virus Glycoprotein. *J. Biol. Chem.* 292 (40), 16527–16538. doi:10.1074/jbc.M117.802090

Zhang, X., Deng, H. W., Shen, H., and Ehrlich, M. (2021). Prioritization of Osteoporosis-Associated Genome-wide Association Study (GWAS) Single-Nucleotide Polymorphisms (SNPs) Using Epigenomics and Transcriptomics. *JBMR Plus* 5 (5), e10481. doi:10.1002/jbpm.10481

Zhi, X., Zhang, J., Cheng, Z., Bian, L., and Qiu, J. (2019). Withdrawn: circLgr4 Drives Colorectal Tumorigenesis and Invasion through Lgr4-targeting Peptide. *Nat. Cancer* doi:10.1038/s41556-018-0194-0

Zhou, M., Guo, S., Yuan, L., Zhang, Y., Zhang, M., Chen, H., et al. (2017). Blockade of LGR4 Inhibits Proliferation and Odonto/osteogenic Differentiation of Stem Cells from Apical Papillae. *J. Mol. Hist.* 48 (5–6), 389–401. doi:10.1007/s10735-017-9737-0

Zhu, J., Hou, Q., Dong, X. D., Wang, Z., Chen, X., Zheng, D., et al. (2015). Targeted Deletion of the Murine Lgr4 Gene Decreases Lens Epithelial Cell Resistance to Oxidative Stress and Induces Age-Related Cataract Formation. *PLoS One* 10 (3), e0119599. doi:10.1371/journal.pone.0119599

Zhu, P., Wu, J., Wang, Y., Zhu, X., Lu, T., Liu, B., et al. (2018). LncGata6 Maintains Stemness of Intestinal Stem Cells and Promotes Intestinal Tumorigenesis. *Nat. Cell Biol.* 20 (10), 1134–1144. doi:10.1038/s41556-018-0194-0

Zhu, Y.-B., Xu, L., Chen, M., Ma, H.-N., and Lou, F. (2013). GPR48 Promotes Multiple Cancer Cell Proliferation via Activation of Wnt Signaling. *Asian Pac. J. Cancer Prev.* 14 (8), 4775–4778. doi:10.7314/apjcp.2013.14.8.4775

Zou, Y., Ning, T., Shi, J., Chen, M., Ding, L., Huang, Y., et al. (2017). Association of a Gain-Of-Function Variant in LGR4 with central Obesity. *Obesity* 25 (1), 252–260. doi:10.1002/oby.21704

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Yang, Wang, Gong, Fan, Yang, Cui, Gao, Li, Sun, Li and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.